Bioventus Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive L
Consolidated Statements of Operations and Comprehensive Loss
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Net sales | $573,280 | $512,345 | $512,117 |
| Cost of sales (including depreciation and amortization of $41,882, $48,503 and $45,622, respectively) | 185,054 | 184,152 | 181,037 |
| Gross profit | 388,226 | 328,193 | 331,080 |
| Selling, general and administrative expense | 340,894 | 303,879 | 332,134 |
| Research and development expense | 13,639 | 13,446 | 23,854 |
| Restructuring costs | (52) | 840 | 6,779 |
| Change in fair value of contingent consideration | 1,423 | 719 | 1,102 |
| Depreciation and amortization | 7,652 | 8,842 | 9,748 |
| Impairment of assets | 36,357 | 78,615 | — |
| Impairment of goodwill | — | — | 124,697 |
| Loss on disposals | 292 | 3,577 | — |
| Operating loss | (11,979) | (81,725) | (167,234) |
| Interest expense, net | 38,792 | 40,676 | 12,021 |
| Other (income) expense | (1,645) | (1,290) | 9,770 |
| Other expense | 37,147 | 39,386 | 21,791 |
| Loss before income taxes | (49,126) | (121,111) | (189,025) |
| Income tax (benefit) expense, net | (5,293) | 85 | (44,374) |
| Net loss from continuing operations | (43,833) | (121,196) | (144,651) |
| Loss from discontinued operations, net of tax | — | (74,429) | (68,740) |
| Net loss | (43,833) | (195,625) | (213,391) |
| Loss attributable to noncontrolling interest - continuing operations | 10,291 | 24,458 | 40,732 |
| Loss attributable to noncontrolling interest - discontinued operations | — | 14,937 | 13,955 |
| Net loss attributable to Bioventus Inc. | $(33,542) | $(156,230) | $(158,704) |
| Net loss | $(43,833) | $(195,625) | $(213,391) |
| Other comprehensive loss, net of tax | |||
| Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment | 13 | (8) | 133 |
| Change in foreign currency translation adjustments | (4,194) | 1,140 | (501) |
| Comprehensive loss | (48,014) | (194,493) | (213,759) |
| Comprehensive loss attributable to noncontrolling interest - continuing operations | 11,105 | 24,230 | 40,811 |
| Comprehensive loss attributable to noncontrolling interest - discontinued operations | — | 14,937 | 13,955 |
| Comprehensive loss attributable to Bioventus Inc. | $(36,909) | $(155,326) | $(158,993) |
| Loss per share of Class A common stock from: | |||
| Continuing operations, basic and diluted | $(0.52) | $(1.54) | $(1.70) |
| Discontinued operations, basic and diluted | — | (0.95) | (0.89) |
| Loss per share of Class A common stock, basic and diluted | $(0.52) | $(2.49) | $(2.59) |
| Weighted-average shares of Class A common stock outstanding, basic and diluted: | 64,547,474 | 62,647,554 | 61,389,107 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.